Research programme: telomerase inhibitors - Morphochem/Sosei

Drug Profile

Research programme: telomerase inhibitors - Morphochem/Sosei

Alternative Names: SOT-095; Telomerase inhibitors research programme - Morphochem/Sosei

Latest Information Update: 29 Feb 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Morphochem AG; Sosei
  • Class Macrocyclic compounds; Oxazoles
  • Mechanism of Action Telomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 01 Dec 2005 Morphochem AG has been acquired by Biovertis AG
  • 18 Dec 2003 Preclinical trials in Cancer in Japan (unspecified route)
  • 18 Dec 2003 Data presented at the 45th Annual Meeting of the American Society of Hematology (ASH-2003) have been added to the Cancer pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top